Tyra Biosciences Inc Dossier
Qualitative Analysis
Business overview
Tyra Biosciences, Inc. (NASDAQ: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's proprietary in-house precision medicine platform, SNu0005P, enables rapid and precise drug design through iterative molecular structural snapshots. This platform helps predict genetic alterations most likely to cause acquired resistance to existing therapies, allowing Tyra to design highly selective small molecule inhibitors that minimize off-target toxicities associated with first-generation pan-FGFR therapies. Tyra's initial focus is on applying its accelerated drug discovery engine to targeted oncology and genetically defined skeletal conditions.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing dabogratinib (formerly TYRA-300), the first orally available, FGFR3-selective inhibitor, in three potentially pivotal clinical studies to support regulatory submissions with the aim to commercialize in three potential blockbuster indications: low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH).
Expected impact: Aims to establish dabogratinib as a best-in-class and first-in-class selective FGFR3 inhibitor, disrupting current procedure-based treatment paradigms and addressing high unmet medical needs.
Utilizing the proprietary SNÅP platform to design next-generation selective FGFR inhibitors and advance early-stage pipeline candidates, including TYRA-200 (an FGFR2 inhibitor) and TYRA-430 (a pan-FGFR inhibitor), into Phase 1 clinical trials.
Expected impact: Enables rapid and precise refinement of structural drug design to overcome acquired drug resistance mutations, expanding Tyra's reach into additional FGFR-driven indications.